Jefferies downgraded Vistagen (VTGN) to Hold from Buy with a price target of 90c, down from $15 after fasedienol failed to meet the primary endpoint in Phase 3 PALISADE-3 study for social anxiety disorder. Though the next Phase 3 readout of the PALISADE-4 study remains on track, the firm’s confidence decreases “significantly” and it says Vistagen has become “a show-me story.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen downgraded to Hold from Buy at Maxim
- Vistagen downgraded to Market Perform from Outperform at William Blair
- Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss
- Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
- Vistagen downgraded to Hold from Buy at Stifel